Search results
Showing 661 to 675 of 2106 results for technology appraisal
Awaiting development Reference number: GID-TA11747 Expected publication date: 14 April 2027
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
Awaiting development Reference number: GID-TA11813 Expected publication date: TBC
Disease-specific reference case extension: management of overweight and obesity in adults (PMG50)
This NICE disease-specific reference case extension describes standardised methods for health economic evaluations of interventions for managing overweight and obesity in adults. For further details on developing and implementing disease-specific reference case extensions, see NICE’s position statement on use of disease-specific reference models in economic evaluations
Awaiting development Reference number: GID-TA11657 Expected publication date: 07 April 2027
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 425.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Awaiting development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
In development Reference number: GID-TA11220 Expected publication date: TBC
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
In development Reference number: GID-TA11836 Expected publication date: TBC